<SUBMISSION>
<ACCESSION-NUMBER>0000950123-09-070778
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20091207
<ITEMS>5.02
<ITEMS>9.01
<FILING-DATE>20091215
<DATE-OF-FILING-DATE-CHANGE>20091215
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>NEOGENOMICS INC
<CIK>0001077183
<ASSIGNED-SIC>8734
<IRS-NUMBER>742897368
<STATE-OF-INCORPORATION>NV
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>333-72097
<FILM-NUMBER>091241073
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>1726 MEDICAL BOULEVARD, SUITE 201
<STREET2>SUITE 201
<CITY>NAPLES
<STATE>FL
<ZIP>34108
<PHONE>9419231949
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>1726 MEDICAL BOULEVARD, SUITE 201
<STREET2>SUITE 201
<CITY>NAPLES
<STATE>FL
<ZIP>34108
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>AMERICAN COMMUNICATIONS ENTERPRISES INC
<DATE-CHANGED>19990120
</FORMER-COMPANY>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>g21568e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e8vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>Washington, DC 20549</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section&nbsp;13 or 15(d) of the<BR>
Securities Exchange Act of 1934</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Date of Report (Date of earliest event reported)<BR>
December&nbsp;7, 2009</B></DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B><FONT style="border-bottom: 1px solid #000000">NEOGENOMICS, INC.</FONT></B>
</DIV>

<DIV align="center" style="font-size: 10pt">(Exact name of registrant as specified in its charter)</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Nevada</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>333-72097</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>74-2897368</B></TD>
</TR>
<TR style="font-size: 1px">
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(State or other jurisdiction of <BR>
incorporation)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Commission File Number)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(I.R.S. Employer<BR>
Identification No.)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>12701 Commonwealth Drive, Suite&nbsp;9, Fort Myers,</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><B>Florida</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>33913</B></TD>
</TR>
<TR style="font-size: 1px">
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(Address of principal executive offices)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Zip Code)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>(239)&nbsp;768-0600</B><BR>
<DIV style="margin-top: 1px"><FONT style="border-top: 1px solid #000000">(Registrant&#146;s telephone number, including area code)</FONT></DIV></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</TD>
</TR>

</TABLE>
</DIV>

<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<!--TOC-->
<!--/TOC-->






<!-- link1 "Item&nbsp;5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers" -->
<DIV align="left"><A NAME="000"></A></DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Item&nbsp;5.02.</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Departure of Directors or Certain Officers; Election of Directors; Appointment of
Certain Officers; Compensatory Arrangements of Certain Officers.</B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Effective as of December&nbsp;7, 2009, Jack G. Spitz, age 54, has been appointed to the position of Vice
President of Laboratory Operations of NeoGenomics, Inc. (the &#147;<U>Company</U>&#148;). Mr.&nbsp;Spitz most
recently served as Executive Director of Operations for Dermpath Diagnostics, a division of Quest
Diagnostics, and formerly a division of Ameripath, Inc., where he was responsible for running
operations of five (5)&nbsp;dermatopathology laboratories across the Southeast United States. Prior to
joining Ameripath in 2006, Mr.&nbsp;Spitz was employed by Genova Diagnostics, an international esoteric
clinical laboratory, as Director of Laboratory Operations from 2000 to 2006. While at Genova
Diagnostics, in addition to operational responsibilities, Mr.&nbsp;Spitz was also involved in many R&#038;D
projects, including ground up development of a genetic testing laboratory and he was responsible
for the transition of tests from R&#038;D to operations. Mr.&nbsp;Spitz received a B.A. degree in Pharmacy
from the Medical University of South Carolina and a B.A. degree in Microbiology from the University
of South Florida.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">NeoGenomics Laboratories, Inc. (&#147;<U>NeoGenomics Laboratories</U>&#148;), the Company&#146;s wholly-owned
subsidiary, and Mr.&nbsp;Spitz are parties to an offer letter dated November&nbsp;9, 2009 (the &#147;<U>Offer
Letter</U>&#148;) with respect to Mr.&nbsp;Spitz&#146;s employment as Vice President of Laboratory Operations. The
Offer Letter provides that Mr.&nbsp;Spitz&#146;s start date would be on or before December&nbsp;7, 2009 and that
his salary would be $210,000 per year. Beginning with the fiscal year ending December&nbsp;31, 2010,
Mr.&nbsp;Spitz is also eligible to receive an incentive bonus payment which will be targeted at 30% of
his base salary based on 100% achievement of goals set forth by the President or CEO of NeoGenomics
Laboratories and approved by the Board of Directors for such fiscal year. Mr.&nbsp;Spitz is also
entitled to participate in all medical and other benefits that NeoGenomics Laboratories has
established for its employees. Mr.&nbsp;Spitz will also be eligible for up to four (4)&nbsp;weeks of paid
time off per year.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Offer Letter also provides that Mr.&nbsp;Spitz will be granted an option to purchase up to 150,000
shares of the Company&#146;s common stock at an exercise price equivalent to the closing price per share
at which such stock was quoted on the NASDAQ Bulletin Board on the date prior to Mr.&nbsp;Spitz&#146;s start
date. The option has a five year term, subject to continued employment, and 37,500 shares of such
option will vest on the first anniversary of employment and 3,125 options will vest each month
thereafter beginning on the 13<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> monthly anniversary of Mr.&nbsp;Spitz&#146;s employment.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">If NeoGenomics Laboratories terminates Mr.&nbsp;Spitz without &#147;Cause&#148; (as defined in the Offer Letter)
then the Company agreed to pay Mr.&nbsp;Spitz&#146;s base salary and maintain his employee benefits for a six
(6)&nbsp;month period from the date of the termination notice.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Company and Mr.&nbsp;Spitz entered into a Confidentiality, Non-Solicitation and Non-Compete
Agreement in connection with the Offer Letter. NeoGenomics Laboratories and Mr.&nbsp;Spitz also entered
into a Relocation Agreement in connection with the Offer Letter pursuant to which NeoGenomics
Laboratories agreed to reimburse Mr.&nbsp;Spitz for up to $35,000 in the aggregate for certain
commuting, temporary housing and permanent relocation expenses. Mr.&nbsp;Spitz further
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 2 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">agreed to return a portion of such reimbursed relocation expenses to NeoGenomics Laboratories in
the event he resigns from his employment within the time period specified in such agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">A copy of the press release announcing the appointment of Mr.&nbsp;Spitz is attached hereto as Exhibit
99.1.
</DIV>
<!-- link1 "Item&nbsp;9.01. Financial Statements and Exhibits" -->

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;9.01. Financial Statements and Exhibits.</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Not applicable</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Not applicable</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Not applicable</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Exhibits.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="4%" nowrap align="left">99.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Press Release of NeoGenomics, Inc. dated December&nbsp;15, 2009</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->- 3 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>
<!-- link1 "SIGNATURES" -->

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SIGNATURES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>NEOGENOMICS, INC.</B><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>

<TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Jerome J. Dvonch
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Jerome J. Dvonch&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Principal Accounting Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Date:
December&nbsp;15, 2009
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->- 4 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<!-- link1 "Exhibit&nbsp;Index" -->

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>Exhibit&nbsp;Index</B></U>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="92%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Exhibit No.</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Description</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press Release of NeoGenomics, Inc.
dated December&nbsp;15, 2009</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->- 5 -<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>g21568exv99w1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv99w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;99.1</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="g21568g2156801.gif" alt="(NEOGENOMICS LOGO)">
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>NEOGENOMICS, INC<BR>
PRESS RELEASE</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>NeoGenomics Announces the Appointment of Jack G. Spitz<BR>
as Vice President of Laboratory Operations</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Ft.
Myers, Florida &#151; December&nbsp;15, 2009 &#151; </B>NeoGenomics, Inc. (NASD OTC BB: NGNM<B>) </B>announced today
that Jack G. Spitz has been appointed Vice President of Laboratory Operations. Mr.&nbsp;Spitz will be
responsible for managing all laboratory operational affairs of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Spitz most recently served as Senior Executive Director of Operations for Dermpath
Diagnostics, a division of Quest Diagnostics, and formerly a division of Ameripath, Inc. Mr.&nbsp;Spitz
was responsible for running operations of 5 dermatopathology
laboratories across the Southeastern United States. Prior to joining Ameripath, Inc. in 2006, Mr.&nbsp;Spitz was employed by Genova
Diagnostics as Director of Operations. While at Genova Diagnostics, in addition to operational
responsibilities, Mr.&nbsp;Spitz was also involved in many R&#038;D projects, including ground up development
of a genetic testing laboratory and was responsible for transition of tests from R&#038;D to operations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Douglas VanOort, Chairman and Chief Executive Officer, stated, &#147;We are very pleased to welcome
Jack Spitz to NeoGenomics. Jack brings strong operating experience in specialized laboratory
testing, including histopathology, dermatopathology, and genetic testing. His process management
skills will be very helpful as we maintain the highest quality and service levels even as we
continue our rapid growth.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>About NeoGenomics, Inc.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NeoGenomics, Inc. is a high-complexity CLIA&#150;certified clinical laboratory that specializes in
cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The
company&#146;s testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow
cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in
Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the
needs of pathologists, oncologists, urologists, and hospitals throughout the United States. For
additional information about NeoGenomics, visit <U>http://www.neogenomics.org</U>.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For more news and information on NeoGenomics, please visit <u>www.IRGnews.com/coi/NGNM</u> where you can
find a fact sheet on the company, investor presentations, and more. Interested parties can also
access additional investor relations material, including an investment profile and an equity
research report, from Hawk Associates at <u>http://www.hawkassociates.com</u> or from the American
Microcap Institute at <u>http://www.americanmicrocapinstitute.com/ngnm/</u>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>For further information, please contact:</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="50%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>NeoGenomics, Inc.</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>The Investor Relations Group</B></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Steven C. Jones
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><I>Investor Relations:</I></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Director of Investor Relations
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Michael Crawford</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">(239) 325-2001
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(212) 825-3210</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><U>sjones@neogenomics.org</U>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><U>mcrawford@investorrelationsgroup.com</U></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">or</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Hawk Associates, Inc.</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><I>Media Relations:</I></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Ms. Julie Marshall
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Janet Vasquez</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">(305)-451-1888
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>(</B>212) 825-3210</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><U>neogenomics@hawkassociates.com</U>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><U>jvasquez@investorrelationsgroup.com</U></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g21568g2156801.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g21568g2156801.gif
M1TE&.#EA1@"``.8``+;$U6IMG1@MB[NUK-KAZ):0B]C7U).JQ\;!NOS]\U!E
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M\OKW]^7@X/?[^XV0NM7/T:VPS.OHZIV>QN'Q\V%OJ/[^_O___R'Y!```````
M+`````!&`(````?_@'^"@X2%AH>(B85^?H.,CXV*DI.4DXR#;YE_<I&5GI^3
MF1D9?V\U&S&<H*NLBZ,.1G8$6S4OG:VXGD89#@YR#!-B7@ZYQ9YR;PX),5PX
M*78)I,;3AHU^<B^]7DX812C1U-.0&5U(2-\)=FD80T$Q5M+AK9F0?WXO+S$S
M*$4"&%DH'-B2ATO'FTA&[.G0\<(+C2$8'GA`DD`505;T&&5ZHP-)BPD0!5A`
M9R?AQ421;D'BF,E(##=P0H8AD*"FG5LG"=UKE*'3FU09K%AY8\<+`!P8_`T9
MD2V!@W@YJT'JQ$M9`A1!LH1D!Z"&E:==>D8]M%/CHY\U9@29\`!#4@P5_SR@
M@&)PU,&QU5Y0H`"#PL98!`Z$<>M6@(P1,V*\N.OG+L&4]?S4P`*!`XO*-6I,
M.:$@J3\!0P[H@4(G@QR3C7$:,[+8ST(=4#(@F=.CP0`6+`8T4)&EK8#?29T$
M`8=WT&F-4#*!<;$@3APV;MP<Z!,2.`8<11C8>5I\D!$C;SA)YH#`-IL-0:8/
M^<V>W8$@,YQV41TUM1$4)"#87N!B#(W!A0$W1`0TN-!!30[$8%)Q&KT`@PM-
MZ`;!!ERD4!UP`J1P@`JV08`%'3'$\`8BEQ33"2-@L+#```,TL<$8<+`G8U(1
M'$"`'A#$L2(>(=@10V.EE.A8+GX8P<@+>B"P`/\55/006`5O62?&`2"T$4``
M-``Q!00K#F!`!P/U1!^1&5#@0@,-Q($`%B-T-B,&"A3!!PI>L/%!'U%\8$((
M*K*(@`L4/$+0&Q2P@`"+YQ&@E6<81E#""33D<4(>:42A0!11W&&"'BS8-@`"
M!E`0YIB"E%CJ5/98@44/+"[@)`!]R/C;`W@^X40*3N3Z1`1A**#%&A>L<0(!
M'/2P8@,]8`&&F-;@E-H?&8#G&A10.-"%@STXIR86!%C@FXQ"!.%C6*/\\0()
M>>RA[AXB"'&!%GGH@04;:#9Q!@PO0&'+/:.0DEHG1NI`1VR%'CK``@8`D<<3
MZ[4G0`6V/A%Q%!)'4<'_Q1??6D$??5P@P@TM[,!D<WB(VF]8CH@EB+0"D]<`
M%0.X$(()6_1107NA`:"SSC?T?(,%3T2AA1`EW`!`SP`PD4<`'&=A`@\&-*<C
M"QWP@G*1N^AD1`U+&,OB&6XP`0+38;17P0$>I.W!!FI[4$0:6<1=Q`@CJ#U&
MV@!DP;$0(#"AA]>?4CWB'T9@\]0C&71@J)\&D*#"%6NLD4;9H#T01A011,#Q
ME1$H$,8##U001A@1I-!&"IFCGD(*8B@0^057Y#$%>2P.D*P51<J!Q.&VP.!I
M`RX`P80(P5YQPQ@0#6$!`WO1,<?S%,RQ`0UW@+"'"2UXH;WV>Z'0/`4$:&#E
M_P6P`P`U!"Q",,<++CG5TQLOI(@`]@2``*P0)TPQ@QIN.5&$"F8(H`#-<("*
M/>$``TR@``'0@#)(X`ADR(,0`K"&.WB@!1M8`ACT0(<B):`+!WF#'NXU@Q8L
M+5AWV``T9E`%.,%A"S",X18TX+DP5"`*67BA#'>X!2*(X0@2D(`26#`#`OP`
M6&L``0-(@``$Z,&#(&Q,'72#KBOU;0Y(R,8,MM`-/O"!`5[\(A\`8($R<L&+
M#`!C&+_(`"\00`HKD$`<5]"#W<4`!?5;0P`\X()/S>$@3\E`)K"@FQV<X`)5
M($`-:@(;,)1``&&0@08F*4DG\$IT$7#")#>Y24EJH/\*6TA"$).@A`7,``FI
M>$$&./"!/?81`3!X@VP(UQ-"-H`$A_S!38K4BQD4@1UF,($P30"`$FCA"3)0
MP3"7:0((./,+1R""'$59!@@,SAZ"@($(`L"$5\*@%RNK)15S^:-K="$!,T`>
M!@Y`-[K1(&Y9F%L[Y^F!'9B@#$0@0A)R($<J+,$6C,GF-KOYJ6\2@Y9^L"4N
M+_"#<LJ!%PGP0@K<4@$9I,"&HFL#)SG9!C$0807Z3`(I;<""&C1+4'_0)C>]
M"4Z$*C27JI!#%Y01@QOXHP)%(*,%T-8"(+3@IS_=01-Z^-%\)N$+9P`#/1Q1
M(I42%)8MW45"Q\G0A)BS%V__\$(4W#*$T54@!7"0I`QB*`4'CE*?90#4"TQ:
M(FE$PJDL/:A47\K01A3.#[T@A0>V4H$)G."O?_V!!CPJRB!*H`QLH(""%/'6
M@<8UG%.]92Z_\QV>D&(&-VA8:(*``BN$H`D%6$$."GM8!/P3&Z3"9DH=6]"H
MBE.R##U-6*PQB@2T0"M*D8$!>E``?DH@!_Q4@@TX4(/O6`0E`EUI:^7ZVH7^
M0`XRA8IL"+"'*$#D.DI0PF_Y"5PI&$"IIP&/)9+[5(-"EJ[/E>GA(O$")JBK
M")8*@"CS^5$R[``%T"7<&XR4->2N5KE096YDG;L@,0G"#AL`@05.4(85B/:W
M*RC`_QE*(P<[0)<J4*E&-EM97M<.>+*#,+"Y=D"&'HHR"4=(@AB&\(`#>$$H
M.KBK=XQTJD5L&,#F=2E5?U#@$LG!`&7@;@Z40(8J7'<(']A`+7;GK\*=IL8Z
MN7&'!8S>'D>"`E\8)2F;T`(&'("O7/`"17H2+>B:1&6.D/)C=0Q;'F.B,6^@
M@Q2.`-PDM`$';=@"`$9@!LJ!)@TM2(`.7L$=0618M3#@\)JE.L4V+V@C+^@!
M&B:]@CM8(`L'**`"*E`=MXAA";"Q`H)"K.&4*GJYD&TT@3%!%PHTN`T=%5T?
ML@"`-O(A""8`B6<>D!T[Q.=P)%(SJA&J:A`+8B$OP`(_"_^`!Q/0X`DVO-P3
M)J"&/1=A,$J!PQC$+,@1T3C*IL:QAXM=U1`SP@#1W,,8^.`%/OPL"T\0@D7%
M((8V=(8P&$C!&%``'F\[2]@!3O6.S[R0-T!@!1.(``YP(`8-G``$(K#`'0`0
M!"\P(`A<.(!U"3,$%7AA,>0PDA^:S(A$BUO`Y'9S3Q;BAP5\`0PUX`$!3/"V
M"#Q@"$.HZ`WFX!0D>,$,;7F+#!A`D70\U`%6@.YI3#YE@3L:6GZ@RQL0L((?
M^&`#ZXNQ'+S@@COT`:.DD\$$`,"%"'@F(B-PP(&L1CC*AN#4`2?VP*&>G!>X
MX`@:U4"NTG"`&YC@13?8`]RR,('_"<S0DIU^``T.%$A(&.'M)W?ZJM\G2RRL
M@`Q`X(/;2N"$CC9<!C)X0MQHX`&+CP$`[^RT!5KP`D[(4DR0;[K<G[YRV-0`
MFC98'W1C8`<4,&`,9H"#S7&.`QD``#W:\X";_+%'"V=@T`#/,:/G_CX=C!P/
M<2P`%5P`!CG<$1H).$<0BB"Q"%QLX6V`PP2P35$/O$.0T1\W]5TSZ`S<G@@=
M38$"]I^"1YE@"NA@``^W!Z1'`$WP`Q9U,\#Q``!03M#"=(O6$RF7$"L'!2/W
M!AR@!")%!G4#`&I0!9XD`W!0`C0P`7=0/:2'`DA00C!R=A4P`BCP>A`X;--'
M>],R<FNU_P!QE`-DL`%`X`4H8`<7YVQ58$F?,SI14`1`<$IVT`(RT!X1$`1(
M,`H\`'?2)X'4]WS6UQ@)T`%9ED\.5@4G8`($P`!!V'L8=P`7<',/$`%;<`(`
MX`%C$`'MX0U/4861-WNK9FBFDE`%$$VP-H(*L'`-=P(CD#TS``0W<`?PE@9I
MH'"@PR@*$`2[@(>R5X-["'4IL1@P\(5$H`$F0"<D8`(G``?ZIP`1H`%AE04@
M0`-3<$=Z,`+D]Q8'4!.6&(%^,('FQEZ-T0588`/`E0.7=P+*1`!>%`0;P`8_
M4`4T=#%],`'*M`,\$`0MA`%]X`4)P`=6*']/QX<I<1"C``94X/];/L1P&C4!
M-^`!0=!&7C`&);`&GK-_&E4"!P`E#\``#M`"VXAR<^>-@O`"I4`*`N$"9D5*
M*G!Z<#"(%=`&5:`&7.`!-&`!>^`!%Y=Q-(1S0>`\^T@*C(8FF2ABBR!32_"'
M<70$7X`%VL,',Z<&3J``H/,`%R`#!$`!*/`-7M`900`%<S!0!O`I5<,='=F-
MFE@(A9,*T#4'#4`$*?91L*8!$V`"2V`'+Q`"(S`!GE,!.*``3ED$;2$N3M63
M"/"3'"F!'FEL0TD(19D**((`98`&070$$;8%J^,$TZ8&15`"<*,S$P`';3$$
M?""$/.F3O#"6N5B6Y>:/T%(JW@<>.B#_$%9@`+T51"OP!4OP>P`P`3(`:S@@
M.B7`!6/`!6VA`"A0`U\IF$")A=TX"B@U8ZJ$=(+D!S`@!=QU6&PP`E,`A-HS
M!FEP`5B)%$E1`DC@68&)`'/0+WJ82Z1F#ZD%=0<!!E1G6'>&?E70!`2@`CO%
M!5$P*Q.1CSS9`&PP!U!WG`R5G*:"$M>`#Y`91,!5!B:@`GO9!A40.E#B#R7P
M<4@0`MWYG>&)B<AI:%"&$K8@+<D&C')$!`6@!FIP`US`!=3A&0JP`?B0`5_I
MG>`I%OPYGOZIG).@,B$$!@V@7?QT!&*0E0K0,*`!`/%A?1.JGQ:*F@2V"VZU
MG(4@2P?A!Y")_P8Y@']PT`>,LD[?,!2P&9@L:E<N.EDP^I^4P`AB8@4P8`,K
M`)\7(A)$AP3SX0<\(*052J2Y.'!'JJ&>`&?[A4XM8&0!DA1#)TL79J4<UI-#
M*IX\UJ7E&0J-P1HS,`(R<"'L@`,G$!"+(4L.8(ELFJ5N^AWEXJ658`OXP`)I
M\"W^P`YBD`0K@`!>P!&JE`!+@*6:N!$<H!N;<0%W,`4^PAW7(!Y&T`4S10Y=
MD`J[8"V\%P0_<%TX\P$:0%H-0`%#40XF,$%,`):!<A"O\0*YT00AX`,4=`4^
MT`(U,(778@>R5`X482W.^@(4,0,;4`+SR2@"X`1<<`.@M(,Y@`!@0/\'U*5'
MW#0%2@(#<UIP;^`&+K`$,N<#Q!,`FL(#NP,;X-@3T#53HD8'7K`!=Q!TLH)S
M>"(Z84!80L0&/@`Y2?1_'0`#'*!4]%"C-=`!.X``;#`%&_`#[B($>Z!(;P"D
M&Y$,-<&O'C`!4%(8A/$`)>`#/@`"0M`'`5`%4@!'5B($P&*L!+`!38``'$`'
M(<LL?L`!:-(B/1`V54`^L0,$S-HO>%43>.0M9<H>3V`&8T``8[`'$G<#7]0"
M/T!!>O0#.\`"35`O!N"SC6$0S;*NM3$`5(`P/```(A`Y5V`"%F8.?T`1/%`$
M)QNP#\!P](8#+`8Z"C"/OW(!,8L%9\`B#7#_!AV`!):58=@P`VZ@)''P*00P
M!33@+IZZ`6+6$`"P?.WQ`%G`!4'@!CE;!'$3<2,``#O:,2(``I"J&TV0+([;
M5H::&HEC*&FR`!`P!1ZP!VO0!U<P+!MPI[+B%@IP``!@`F=@`"9P`/"4!S-W
M!TQCK$!`D!+P!3W``1V0'$72+ZII60:Q$+(1`@;`!G'0`'\R!290`AQC,STJ
M`)GD!)YDA#9D.6'@,<"B!32P`14[``4@`51P(+!A@:_W/I=@%P4,&PS1`:S"
M(DW``D!P;<<;`<<W!4``!$$P!C]31A:0!\44!7T@!!.P`ZOB'&R090A`%RQ\
M$.3R!A;H$V#*9.>T_P0&TP2P(BN@40%_RW`X\)*@$P86H`578D$\X#4-``$A
M(`42L``LP1)*JA&*(!]R8"TH@`4(H`9[&Q'YJP46,`)C<#?0FP4?<`=YD`47
MP#$B``!3T"<#@!D-$$<E%:>5`!95W`5R,`,\H`'6D0(Z<P>1LP4L"P):4,AW
M<`.$'``?0`,[L`-GL+NA`@//608P1\>>@,?D\`)VL%=),01.T`2].P4)2SZ?
M$SJ6HP7!`@(^F+AM"P&CL03`"%Q44"37!`H&43A_H`,QX`5P0%%SXQQ-L@13
ML`>HW`=/D`9W4D%,P"<&XR%6``:\95@%@`6K:<L'D1`Z(`=\T!E#$&8H4/\'
M;%`[!C`'3$"]>!(`0I`'<\`!Z*.^+``&4RD%2D!G0F0`0%(0CI'-!/```G`#
M=E"O8&``AZ(C'``$-)/.!!`"Z*,;@&('OJ.!OR5'/5`#QH`U@F`M>Q4!#$`'
M7Y$!=F`'4-,E$$`".4L"YZL;8$.:"-!;^11<$$#1QD`.<G#173`"0P`'P4F^
M2.!],8`C7<("DCP`<0`!=0!S+/`%.4!G(G58+F`%U)"JJH#10T`&I_0"#"%(
M^2`'DY$C>``#;1LJ<X`'6>:6]"P!4H`%S&(,F6!FX1<$.`"<_;(1=E4X8%`'
M+*`'/%(#$!!:=!:,0M0#8-`(0Y(+MZQ>NTQ#*$#_+H;@;:;@6;PE9+ZE!/Y4
MR]2`MJ7Z07;@`S@`!.PC*&=Q#PX"`5^@78857#9@`+5`V>(0";V0("V@`&QP
M&N*AG#M!`6(=1]L57%+PSO@P$(_!VDXA$/>$`JD08H($!GO=UT)6!I.]&,HY
MV*MM:*U-%*?M(V'R`I")V]MU!$J@Q`"%399,$'DE""AP7T:B2D?M6Q&]`E(`
M*-V1"."["36@&!D0`@WDUSE0!C;0U8@JHW@Q"N5@JASP!:(5HF4P`,35IR/G
MW]1P:(8V"AVP`.J=`P70`X&B2C+\WB1""@Y"H$E=38'"5!K.6*WA(`',70VP
M!*H]XHR5`:U7`[(91`7P9%VOR>*50,MV!US9^T^J9*@VCEQ^$`(.M`(-`+$_
M_@E'T@!!!`%&?N2>8`L<X$#@BJ1.3N(((`$VX!<BQ^!.[@=@\`4%L`2T7>6>
<(*':ZR\URN5'#INP="K53.:(8`JQ%-XL'@@`.S\_
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
